H.B. 4382 (113th) would provide $3.7 billion to the Drug and Trauma Treatment Administration (DTTA), the National Institutes of Health (NIH), and the Office of National Drug Control Policy (ONDCP) to increase funding for addiction treatment, research, and other programs, to ensure that we have the resources necessary to combat this epidemic.
The bill was introduced by Senator Bernie Sanders (I-VT) on February 10, 2017.
H. 4353 (113rd) would establish the National Institute of Health as a public-private partnership for drug treatment and research.
The National Institutes and NTAP would jointly develop a new drug treatment plan for opioid addiction.
The NTAP plan would include an expanded focus on treating patients in a safe, non-addictive manner, including by providing treatment through the use of naloxone, a life-saving opioid reversal drug, to reverse the effects of opioid withdrawal.
The legislation was introduced on March 18, 2017 by Senator Elizabeth Warren (D-MA) and Senator Tim Kaine (D) of Virginia.
H. 4351 (113nd) would amend the Controlled Substances Act to provide a tax credit for pharmaceutical manufacturers who develop new or improved treatments for opioid dependence.
This bill would also provide $15 million in additional funding for the National Center on Addiction and Substance Abuse Research to fund studies to better understand the treatment options for opioid use disorders.
This bill was passed in the 114th Congress on February 13, 2018.
A bill to amend the Federal Election Campaign Act to expand campaign finance disclosure requirements for federal election campaigns was introduced in the 112th Congress by Senator Cory Booker (D, NJ) on January 23, 2018 and was referred to the Committee on the Judiciary for consideration on January 29, 2018 by Representative Steve Cohen (D–TN) of the House of Representatives.
On February 13 of 2018, Senator Joe Manchin (D‐WV) introduced H. Res.
936 to authorize the Department of Health and Human Services (HHS) to establish a task force to assess the impacts of opioid misuse and dependence on the United States.
Congressional Review Act HRC 4382 The Congressional Review Act (CRAA) of 2017, also known as the CRAA, allows Congress to nullify any final regulation promulgated by the President or a federal agency that is not within the scope of the agency’s statutory authority.
The CRAA allows Congress, upon notice to the agency, to rescind or repeal any regulation issued by the agency.
This provision was enacted by Congress on October 17, 2017, in the 113th Congress.
Senate Bill H. 8 (H.
R, 8) was introduced to Congress on December 18, 2018 to amend title 18, United States Code, section 301 of title 5, United Kingdom Code, to provide that any law, regulation, or order issued pursuant to this title shall not be construed to confer any benefits on any person, association, or entity if it is inconsistent with any law or regulation of the United Kingdom or of any State in which the individual is a resident or resident dependent of such individual or the State in the jurisdiction of which the person or such association or entity is based, or with any applicable international agreement, including any agreement between a United Kingdom and a United States or any State or the United Nations.
The measure passed the Senate on January 17, 2019, and was introduced again by Senator Chuck Grassley (R-IA) on June 17, 2020.
The Senate version of the measure, H. R. 6, was passed by the House on June 30, 2020, and by the Senate Judiciary Committee on September 27, 2020 and the House again on October 4, 2020 (see below).
HHS Office of Special Counsel Hospitals and medical facilities are required to comply with applicable Federal laws to the extent necessary to maintain patient safety and ensure the security of their facilities, to prevent acts of terrorism, and to provide services consistent with their regulatory authority.
In addition, Federal law prohibits discrimination against any person based on any disability or genetic predisposition, or on any other factor that would otherwise substantially limit a person’s access to health care.
HHS Office of the Inspector General has the responsibility for overseeing the implementation of all laws relating to the health care profession.
The Office of Inspector General’s mission is to conduct a thorough investigation of allegations of violations of Federal law and regulations, to evaluate and assess compliance with Federal laws and regulations relating to such violations, and for other purposes, including oversight of compliance with State and local laws and requirements.
This is an ongoing, and continuing, investigation.
HHS Inspector General is responsible for conducting inspections and reviewing all allegations of wrongdoing in relation to the activities of any Federal agency or any individual.
This report is not intended to provide legal advice and is not legal advice on whether the law is in compliance with this